Phospholipid binding improves plasma survival of factor VIII

References
1 Klinge J, Ananyeva NM, Hauser CA. et al. Hemophilia A--from basic science to clinical practice. Semin Thromb Hemost 2002; 28: 309-322.
2 Lenting PJ, CJ VANS, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 05: 1353-1360.
3 Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von wille-brand factor. J Biol Chem 1997; 272: 18007-18014.
4 Saenko EL, Shima M, Rajalakshmi KJ. et al. A role for the C2 domain of factor VIII in binding to von Wille-brand factor. J Biol Chem 1994; 269: 11601-11605.
5 Lenting PJ, Neels JG, van den Berg BM. et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 23734-23739.
6 Saenko EL, Yakhyaev AV, Mikhailenko I. et al. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274: 37685-37692.
7 Gilbert GE, Kaufman RJ, Arena AA. et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-6381.
8 Meems H, Meijer AB, Cullinan DB. et al. Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity. Blood 2009; 114: 3938-3946.
9 Hsu TC, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood 2008; 111: 200-208.
10 Kemball-Cook G, Barrowcliffe TW. Interaction of factor VIII with phospholipids: role of composition and negative charge. Thromb Res 1992; 67: 57-71.
11 Ramani K, Miclea RD, Purohit VS. et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci 2008; 97: 1386-1398.
12 Purohit VS, Ramani K, Sarkar R. et al. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIIIO-phospho-L-serine complex. J Biol Chem 2005; 280: 17593-17600.
13 Berntorp E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 09: 353-359.
14 Barrowcliffe TW, Raut S, Sands D. et al. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-256.
15 Nedelman JR, Gibiansky E, Lau DT. Applying Bail-er’s method for AUC confidence intervals to sparse sampling. Pharm Res 1995; 12: 124-128.
16 Bovenschen N, Mertens K, Hu L. et al. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906-912.
17 Saenko E, Kannicht C, Loster K. et al. Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay. Anal Biochem 2002; 302: 252-262.
18 Saenko E, Sarafanov A, Greco N. et al. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes. J Chromatogr A 1999; 852: 59-71.
19 Kamps JA, Scherphof GL. Receptor versus non-receptor mediated clearance of liposomes. Adv Drug Deliv Rev 1998; 32: 81-97.
20 Denis CV, Christophe OD, Oortwijn BD. et al. Clearance of von Willebrand factor. Thromb Haemost 2008; 99: 271-278.
21 Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949-6953.
22 Ngo JC, Huang M, Roth DA. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
23 Pratt KP, Shen BW, Takeshima K. et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-442.